STOCK TITAN

[8-K] Lipocine Inc. Reports Material Event

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Lipocine Inc. filed an 8-K reporting a material event: the company submitted a presentation as Exhibit 99.1 for the H.C. Wainwright 27th Annual Global Investor Conference and included the interactive cover page Exhibit 104 in Inline XBRL format. The filing is signed by Mahesh V. Patel, President and Chief Executive Officer, and is dated September 5, 2025. The filing does not include earnings, financial tables, or other material transaction disclosures; it documents public investor-facing presentation materials being made available.

Lipocine Inc. ha depositato un 8-K riportando un evento sostanziale: l'azienda ha presentato una presentazione come Exhibit 99.1 per la 27th Annual Global Investor Conference di H.C. Wainwright e ha incluso la pagina di copertina interattiva Exhibit 104 in formato Inline XBRL. Il deposito è firmato da Mahesh V. Patel, Presidente e Amministratore Delegato, ed è datato September 5, 2025. Il deposito non include utili, tabelle finanziarie o altre divulgazioni di transazioni rilevanti; esso documenta materiali di presentazione pubblici rivolti agli investitori disponibili.

Lipocine Inc. presentó un 8-K informando un evento material: la empresa presentó una presentación como Exhibit 99.1 para la 27th Annual Global Investor Conference de H.C. Wainwright e incluyó la portada interactiva Exhibit 104 en formato Inline XBRL. El registro está firmado por Mahesh V. Patel, Presidente y Director Ejecutivo, y está fechado September 5, 2025. El registro no incluye ganancias, tablas financieras u otras divulgaciones de transacciones importantes; documenta materiales de presentación públicos para inversionistas que están disponibles.

Lipocine Inc.가 중대한 이벤트를 보고하는 8-K를 제출했습니다: 회사는 Exhibit 99.1로 프리젠테이션을 제출했으며 H.C. Wainwright 27th Annual Global Investor Conference를 위해 작성되었고 대화형 표지 페이지 Exhibit 104를 Inline XBRL 형식으로 포함했습니다. 제출서는 Mahesh V. Patel 회장 겸 최고경영자에 의해 서명되었고 날짜는 September 5, 2025로 기재되어 있습니다. 이 제출에는 수익, 재무 표 또는 다른 중요한 거래 공시가 포함되어 있지 않으며, 공개 투자자 대상의 프리젠테이션 자료가 이용 가능하다는 것을 문서화합니다.

Lipocine Inc. a déposé un 8-K signalant un événement important : la société a soumis une présentation en tant que Exhibit 99.1 pour la 27th Annual Global Investor Conference de H.C. Wainwright et a inclus la page de couverture interactive Exhibit 104 au format Inline XBRL. Le dépôt est signé par Mahesh V. Patel, Président et Directeur général, et daté du 5 septembre 2025. Le dépôt n’inclut pas de résultats, de tableaux financiers ou d’autres divulgations de transactions importantes ; il documente des supports de présentation destinés au public investisseurs qui sont mis à disposition.

Lipocine Inc. hat eine 8-K eingereicht, in der ein wesentlicher Ereignisbericht enthalten ist: Das Unternehmen reichte eine Präsentation als Exhibit 99.1 für die H.C. Wainwright 27th Annual Global Investor Conference ein und schloss die interaktive Titelseite Exhibit 104 im Inline XBRL-Format ein. Die Einreichung wurde von Mahesh V. Patel, Präsident und Chief Executive Officer, unterzeichnet und trägt das Datum September 5, 2025. Die Einreichung enthält keine Gewinne, Finanztafeln oder andere wesentliche Transaktionsoffenlegungen; sie dokumentiert öffentlich gekennzeichnete Investorenpräsentationsmaterialien, die verfügbar gemacht werden.

Lipocine Inc. قد قدمت 8-K يورد حدثاً مادياً: قدمت الشركة عرضاً كـ Exhibit 99.1 لـ H.C. Wainwright 27th Annual Global Investor Conference وشملت صفحة الغلاف التفاعلية Exhibit 104 بصيغة Inline XBRL. تم توقيع الملف من قبل Mahesh V. Patel، رئيس مجلس الإدارة والرئيس التنفيذي، ومؤرّخ بتاريخ September 5, 2025. لا يتضمن الملف أرباح أو جداول مالية أو إفصاحات معاملات مادية أخرى؛ يوثق المواد التقديمية للمستثمرين العامة التي أصبحت متاحة.

Lipocine Inc. 已提交一份 8-K,报道一项重大事件:公司提交了一份作为 Exhibit 99.1 的演示文稿,用于 H.C. Wainwright 第27届年度全球投资者大会,并将互动封面页 Exhibit 104 以 Inline XBRL 格式包含其中。该备案由 Mahesh V. Patel,总裁兼首席执行官签署,日期为 September 5, 2025。该备案不包含收益、财务表格或其他重大交易披露;它记录向公众投资者披露的演示材料已公开可用。

Positive
  • Exhibit 99.1 presentation furnished for the H.C. Wainwright 27th Annual Global Investor Conference on September 5, 2025
  • Exhibit 104 Inline XBRL cover page included, improving machine-readable disclosure
Negative
  • No financial results or earnings data were included in the filing
  • No material transactions or new agreements were disclosed in this 8-K

Insights

Company disclosed investor presentation materials at a major conference on September 5, 2025.

The filing registers that a presentation (Exhibit 99.1) for the H.C. Wainwright 27th Annual Global Investor Conference was furnished and that the Inline XBRL cover page (Exhibit 104) was included. This formalizes public dissemination of slides or remarks to investors and satisfies SEC exhibit furnishing requirements.

Because no financial results, guidance, or material agreements were attached, the immediate investor impact is limited to increased disclosure access; monitor any subsequent filings or slide content for new program, clinical, or timeline details over the following weeks.

8-K confirms compliance steps for written communications and exhibit submission.

The submission includes the specified exhibits and a CEO signature, indicating procedural compliance with reporting obligations for investor communications. The form notes checkboxes for solicitation and pre-commencement communications but none are marked, clarifying the nature of the disclosure.

Investors should note that this filing documents disclosure mechanics rather than operational changes; any material developments referenced in the presentation would need their own filings to be separately material and actionable.

Lipocine Inc. ha depositato un 8-K riportando un evento sostanziale: l'azienda ha presentato una presentazione come Exhibit 99.1 per la 27th Annual Global Investor Conference di H.C. Wainwright e ha incluso la pagina di copertina interattiva Exhibit 104 in formato Inline XBRL. Il deposito è firmato da Mahesh V. Patel, Presidente e Amministratore Delegato, ed è datato September 5, 2025. Il deposito non include utili, tabelle finanziarie o altre divulgazioni di transazioni rilevanti; esso documenta materiali di presentazione pubblici rivolti agli investitori disponibili.

Lipocine Inc. presentó un 8-K informando un evento material: la empresa presentó una presentación como Exhibit 99.1 para la 27th Annual Global Investor Conference de H.C. Wainwright e incluyó la portada interactiva Exhibit 104 en formato Inline XBRL. El registro está firmado por Mahesh V. Patel, Presidente y Director Ejecutivo, y está fechado September 5, 2025. El registro no incluye ganancias, tablas financieras u otras divulgaciones de transacciones importantes; documenta materiales de presentación públicos para inversionistas que están disponibles.

Lipocine Inc.가 중대한 이벤트를 보고하는 8-K를 제출했습니다: 회사는 Exhibit 99.1로 프리젠테이션을 제출했으며 H.C. Wainwright 27th Annual Global Investor Conference를 위해 작성되었고 대화형 표지 페이지 Exhibit 104를 Inline XBRL 형식으로 포함했습니다. 제출서는 Mahesh V. Patel 회장 겸 최고경영자에 의해 서명되었고 날짜는 September 5, 2025로 기재되어 있습니다. 이 제출에는 수익, 재무 표 또는 다른 중요한 거래 공시가 포함되어 있지 않으며, 공개 투자자 대상의 프리젠테이션 자료가 이용 가능하다는 것을 문서화합니다.

Lipocine Inc. a déposé un 8-K signalant un événement important : la société a soumis une présentation en tant que Exhibit 99.1 pour la 27th Annual Global Investor Conference de H.C. Wainwright et a inclus la page de couverture interactive Exhibit 104 au format Inline XBRL. Le dépôt est signé par Mahesh V. Patel, Président et Directeur général, et daté du 5 septembre 2025. Le dépôt n’inclut pas de résultats, de tableaux financiers ou d’autres divulgations de transactions importantes ; il documente des supports de présentation destinés au public investisseurs qui sont mis à disposition.

Lipocine Inc. hat eine 8-K eingereicht, in der ein wesentlicher Ereignisbericht enthalten ist: Das Unternehmen reichte eine Präsentation als Exhibit 99.1 für die H.C. Wainwright 27th Annual Global Investor Conference ein und schloss die interaktive Titelseite Exhibit 104 im Inline XBRL-Format ein. Die Einreichung wurde von Mahesh V. Patel, Präsident und Chief Executive Officer, unterzeichnet und trägt das Datum September 5, 2025. Die Einreichung enthält keine Gewinne, Finanztafeln oder andere wesentliche Transaktionsoffenlegungen; sie dokumentiert öffentlich gekennzeichnete Investorenpräsentationsmaterialien, die verfügbar gemacht werden.

false 0001535955 0001535955 2025-09-05 2025-09-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported):

September 5, 2025

 

 

LIPOCINE INC.

 

(Exact name of registrant as specified in its charter)

 

Commission File No. 001-36357

 

Delaware   99-0370688

(State or other jurisdiction

of incorporation)

 

(IRS Employer

Identification Number)

 

675 Arapeen Drive, Suite 202

Salt Lake City, Utah 84108

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (801) 994-7383

 

Former name or former address, if changed since last report: Not Applicable

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4© under the Exchange Act (17 CFR 240.13©(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.0001 per share   LPCN   The NASDAQ Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 8.01 Other Events

 

The Company is presenting and meeting with investors at the H.C. Wainwright 27th Annual Global Investor Conference September 8-10, 2025, in New York City, New York. A copy of the presentation is furnished as Exhibit 99.1 to this report and incorporated by reference herein.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

The following exhibits are filed with this report:

 

Exhibit No.   Description
99.1   Presentation for the H.C. Wainwright 27th Annual Global Investor Conference
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

      LIPOCINE INC.
         
Date: September 5, 2025   By: /s/ Mahesh V. Patel
        Mahesh V. Patel
        President and Chief Executive Officer

 

 

 

FAQ

What did Lipocine (LPCN) disclose in the 8-K filed on September 5, 2025?

The company furnished a presentation as Exhibit 99.1 for the H.C. Wainwright 27th Annual Global Investor Conference and included the Inline XBRL cover page as Exhibit 104.

Does the 8-K include earnings or financial tables for LPCN?

No. The filing does not contain earnings data or financial tables; it only furnishes presentation materials and the interactive cover page.

Who signed the Lipocine 8-K filing?

The filing is signed by Mahesh V. Patel, President and Chief Executive Officer.

Was solicitation or pre-commencement communication indicated in the filing?

No. The checkboxes for solicitation and pre-commencement communications were present but not checked, indicating those categories do not apply here.

Where can investors find the presentation referenced in the 8-K?

The presentation is furnished as Exhibit 99.1 to the 8-K; the filing indicates the exhibit contains the conference presentation materials.
Lipocine Inc

NASDAQ:LPCN

LPCN Rankings

LPCN Latest News

LPCN Latest SEC Filings

LPCN Stock Data

15.88M
5.26M
2.91%
9.81%
1.63%
Biotechnology
Pharmaceutical Preparations
Link
United States
SALT LAKE CITY